ATE383157T1 - Verwendung von gemifloxacin verbindungen gegen bakterien - Google Patents

Verwendung von gemifloxacin verbindungen gegen bakterien

Info

Publication number
ATE383157T1
ATE383157T1 AT00948537T AT00948537T ATE383157T1 AT E383157 T1 ATE383157 T1 AT E383157T1 AT 00948537 T AT00948537 T AT 00948537T AT 00948537 T AT00948537 T AT 00948537T AT E383157 T1 ATE383157 T1 AT E383157T1
Authority
AT
Austria
Prior art keywords
against bacteria
compounds against
gemifloxacin compounds
gemifloxacin
bacteria
Prior art date
Application number
AT00948537T
Other languages
English (en)
Inventor
Peter C Appelbaum
Darren Bast
Diane M Citron
Donna M Crabb
Kim L Credito
Ross J Davidson
Todd Davies
Joyce Deazavedo
Jacques Dubois
Lynn B Duffy
Carla Duncan
Lois M Ernie
Ellie J C Goldstein
Dianne Hoellman
Linda M Kelly
Donald E Low
Glenn A Pankuch
Karen B Searcey
Claude St-Pierre
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9915597.0A external-priority patent/GB9915597D0/en
Priority claimed from US09/395,492 external-priority patent/US20010049378A1/en
Priority claimed from US09/395,851 external-priority patent/US6340689B1/en
Priority claimed from US09/400,144 external-priority patent/US6331550B1/en
Priority claimed from US09/399,855 external-priority patent/US6262071B1/en
Priority claimed from US09/569,648 external-priority patent/US6803376B1/en
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Application granted granted Critical
Publication of ATE383157T1 publication Critical patent/ATE383157T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT00948537T 1999-06-29 2000-06-29 Verwendung von gemifloxacin verbindungen gegen bakterien ATE383157T1 (de)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US14148799P 1999-06-29 1999-06-29
US14145899P 1999-06-29 1999-06-29
US14148699P 1999-06-29 1999-06-29
US14145699P 1999-06-29 1999-06-29
US14145799P 1999-06-29 1999-06-29
US14140999P 1999-06-29 1999-06-29
US14148899P 1999-06-29 1999-06-29
US14145599P 1999-06-29 1999-06-29
GBGB9915597.0A GB9915597D0 (en) 1999-07-02 1999-07-02 Method of treatment
US14272599P 1999-07-08 1999-07-08
US14272499P 1999-07-08 1999-07-08
US14272999P 1999-07-08 1999-07-08
US09/395,492 US20010049378A1 (en) 1999-06-29 1999-09-14 Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria
US09/395,851 US6340689B1 (en) 1999-06-29 1999-09-14 Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
US39966099A 1999-09-21 1999-09-21
US39965799A 1999-09-21 1999-09-21
US39966299A 1999-09-21 1999-09-21
US39966199A 1999-09-21 1999-09-21
US09/400,144 US6331550B1 (en) 1999-06-29 1999-09-21 Methods of use of quinolone compounds against anaerobic pathogenic bacteria
US09/399,855 US6262071B1 (en) 1999-06-29 1999-09-21 Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
US40143299A 1999-09-22 1999-09-22
US40143399A 1999-09-22 1999-09-22
US09/569,648 US6803376B1 (en) 1999-06-29 2000-05-12 Method of use of quinolone compounds against pneumococcal and haemophilus bacteria
US57773200A 2000-05-23 2000-05-23
US57773100A 2000-05-23 2000-05-23

Publications (1)

Publication Number Publication Date
ATE383157T1 true ATE383157T1 (de) 2008-01-15

Family

ID=56437095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948537T ATE383157T1 (de) 1999-06-29 2000-06-29 Verwendung von gemifloxacin verbindungen gegen bakterien

Country Status (7)

Country Link
EP (1) EP1223935B1 (de)
JP (1) JP2003531101A (de)
AT (1) ATE383157T1 (de)
DK (1) DK1223935T3 (de)
ES (1) ES2299430T3 (de)
PT (1) PT1223935E (de)
WO (1) WO2001000209A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
KR100892864B1 (ko) 2001-08-02 2009-04-15 주식회사 엘지생명과학 4-아미노메틸렌-피롤리딘-3-온의 아미노-보호 유도체및/또는 4-아미노메틸렌-피롤리딘-3-알콕시이미노유도체들 및/또는 제미플록사신 또는 그것의 염의 제조를위한 공정
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
DE10235967B4 (de) * 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
MX359219B (es) * 2005-05-18 2018-09-19 Raptor Pharmaceuticals Inc Fluoroquinolonas aerosolizadas y sus usos.
KR20180022971A (ko) * 2015-07-02 2018-03-06 다나-파버 캔서 인스티튜트 인크. 안정화된 항미생물성 펩티드
WO2017151617A1 (en) 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
CA3067047A1 (en) 2017-07-19 2019-01-24 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
CN110060784B (zh) * 2019-06-05 2022-11-08 华中农业大学 鸡毒支原体对达氟沙星的耐药判定标准试验方法
CN111620901B (zh) * 2020-06-08 2023-03-21 蚌埠医学院第二附属医院 一种含硅氧烷基的氟喹诺酮化合物、其制备方法及用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931446A (en) * 1988-03-23 1990-06-05 Abbott Laboratories Antimicrobial for in-vitro diagnostic kits
CA2176298C (en) * 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment

Also Published As

Publication number Publication date
PT1223935E (pt) 2008-04-03
EP1223935B1 (de) 2008-01-09
JP2003531101A (ja) 2003-10-21
DK1223935T3 (da) 2008-02-04
WO2001000209A1 (en) 2001-01-04
EP1223935A1 (de) 2002-07-24
ES2299430T3 (es) 2008-06-01
EP1223935A4 (de) 2004-04-28

Similar Documents

Publication Publication Date Title
DE122011100050I1 (de) Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer.
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
DE60012031D1 (de) Piperazin verbindungen als tachykinin-antagonisten
PT892780E (pt) Analogos de m-amidino fenilo como inibidores do factor xa
DE69716925D1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
ECSP003699A (es) Inhibidores de fab i
CY1115713T1 (el) Παραγωγα ακρυλαμιδιου ως αντιβιοτικοι παραγοντες
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
DE60039183D1 (de) Verbindungen mit antibakteriellen und antiparasitischen eigenschaften
DE60018792D1 (de) Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen
BR0209149A (pt) Ftalazinonas
TR200003384T2 (tr) Arginin türevleri kullanılarak oksazolidinon antibakteriyel maddelerin etkisinin arttırılması
ATE383157T1 (de) Verwendung von gemifloxacin verbindungen gegen bakterien
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
BRPI0409276A (pt) derivados de piperazina inibidores de renina
SE0103710D0 (sv) Compounds
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
EA200100854A1 (ru) Кальций-литические соединения
DK1558580T3 (da) N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner
BR0115996A (pt) Sulfamidotienopirimidinas
GB0103045D0 (en) Organic Compounds
DE60105618D1 (de) Dihydroporphyrinderivate und ihre verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1223935

Country of ref document: EP